Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study).
Mandalà M, Ferrari A, Brecht IB, Suijkerbuijk KP, Maschke L, Giannarelli D, Indini A, Ubaldi M, Pecci G, Atkinson V, Helgadottir H, Chiaravalli S, Benannoune N, Robert C, Teterycz P, Rutkowski P, Puig S, Madonna G, Kebudi R, Grynberg S, Arantes LM, Bien E, Krawczyk M, Pasquale MD, Dierselhuis MP, Massi D, Long GV, Ascierto PA, Eggermont AMM; Melcaya consortium (see appendix for the list of the coauthors belonging to the Melcaya Consortium). Mandalà M, et al. Eur J Cancer. 2024 Nov;211:114305. doi: 10.1016/j.ejca.2024.114305. Epub 2024 Sep 3. Eur J Cancer. 2024. PMID: 39236557 Free article.
Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study.
van der Kooij MK, Joosse A, Suijkerbuijk KPM, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Haanen JBAG, Hospers GAP, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil G, Westgeest HM, Wouters MWJM, Dekkers OM, Kapiteijn E. van der Kooij MK, et al. Among authors: suijkerbuijk kpm. Br J Cancer. 2023 Mar;128(5):707-710. doi: 10.1038/s41416-022-02088-8. Epub 2022 Dec 23. Br J Cancer. 2023. PMID: 36564561 Free PMC article. No abstract available.
Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry.
Rauwerdink DJW, van Doorn R, van der Hage J, Van den Eertwegh AJM, Haanen JBAG, Aarts M, Berkmortel F, Blank CU, Boers-Sonderen MJ, De Groot JWB, Hospers GAP, de Meza M, Piersma D, Van Rijn RS, Stevense M, Van der Veldt A, Vreugdenhil G, Wouters MWJM, Suijkerbuijk K, van der Kooij M, Kapiteijn E. Rauwerdink DJW, et al. Cancers (Basel). 2022 Nov 19;14(22):5694. doi: 10.3390/cancers14225694. Cancers (Basel). 2022. PMID: 36428787 Free PMC article.
Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021.
van Not OJ, van den Eertwegh AJM, Haanen JB, Blank CU, Aarts MJB, van Breeschoten J, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Ismail RK, Kapiteijn E, Bloem M, De Meza MM, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Blokx WAM, Wouters MWJM, Suijkerbuijk KPM. van Not OJ, et al. Among authors: suijkerbuijk kpm. EClinicalMedicine. 2024 Feb 12;69:102485. doi: 10.1016/j.eclinm.2024.102485. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38370537 Free PMC article.
Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis.
De Meza MM, Blokx WAM, Bonenkamp JJ, Blank CU, Aarts MJB, van den Berkmortel FWPJ, Boers-Sonderen MJ, De Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Van Not OJ, Piersma D, Van Rijn RS, Stevense-den Boer M, Van der Veldt AAM, Vreugdenhil G, Van den Eertwegh AJM, Suijkerbuijk KPM, Wouters MWJM. De Meza MM, et al. Among authors: suijkerbuijk kpm. Cancers (Basel). 2023 Jan 7;15(2):409. doi: 10.3390/cancers15020409. Cancers (Basel). 2023. PMID: 36672358 Free PMC article.
Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trials.
de Meza MM, Blokx WAM, Bonenkamp HJ, Blank CU, Aarts MJB, van den Berkmortel FWPJ, Boers-Sonderen MJ, de Groot JWB, Haanen JB, Hospers GAP, Kapiteijn EW, van Not OJ, Piersma D, van Rijn RS, Stevense-Den Boer MA, van der Veldt AAM, Vreugdenhil G, van den Eertwegh AJM, Suijkerbuijk KPM, Wouters MWJM. de Meza MM, et al. Among authors: suijkerbuijk kpm. Int J Cancer. 2023 Jul 15;153(2):389-398. doi: 10.1002/ijc.34485. Epub 2023 Mar 8. Int J Cancer. 2023. PMID: 36843260
Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients.
Rauwerdink DJW, Not OV, de Meza M, Doorn RV, Hage JV, Eertwegh AJMVD, Haanen JB, Aarts MJB, Berkmortel FWPJVD, Blank CU, Boers-Sonderen MJ, Groot JWB, Hospers GAP, Piersma D, van Rijn RS, Stevense-den Boer AM, Veldt AAMV, Vreugdenhil G, Wouters MWJM, Suijkerbuijk KPM, Kapiteijn E. Rauwerdink DJW, et al. Among authors: suijkerbuijk kpm. Cancers (Basel). 2024 Jul 26;16(15):2656. doi: 10.3390/cancers16152656. Cancers (Basel). 2024. PMID: 39123384 Free PMC article.
Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry.
Verheijden RJ, May AM, Blank CU, Aarts MJB, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, Boers-Sonderen MJ, van der Hoeven JJM, Hospers GA, Piersma D, van Rijn RS, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van Zeijl MCT, Wouters MWJM, Haanen JBAG, Kapiteijn E, Suijkerbuijk KPM. Verheijden RJ, et al. Among authors: suijkerbuijk kpm. Clin Cancer Res. 2020 May 1;26(9):2268-2274. doi: 10.1158/1078-0432.CCR-19-3322. Epub 2020 Jan 27. Clin Cancer Res. 2020. PMID: 31988197
145 results